ONO PHARMACEUTICAL CO., LTD. Logo

ONO PHARMACEUTICAL CO., LTD.

Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.

4528 | T

Overview

Corporate Details

ISIN(s):
JP3197600004
LEI:
Country:
Japan
Address:
大阪市中央区道修町二丁目1番5号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ONO PHARMACEUTICAL CO., LTD., established in 1717, is a research and development-oriented pharmaceutical company dedicated to discovering and delivering innovative medicines. With a legacy spanning over three centuries, the company focuses on addressing high unmet medical needs through the creation, manufacturing, and sale of prescription drugs. Its primary therapeutic areas include oncology, immunology, neurology, and other specialty fields, with a portfolio of treatments for conditions such as cancer and type II diabetes. The company is committed to a mission of fighting disease and pain by providing new therapeutic options to patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 01:00
Registration Form
確認書
Japanese 9.1 KB
2025-11-06 01:00
Interim Report
半期報告書-第78期(2025/04/01-2026/03/31)
Japanese 328.6 KB
2025-07-01 09:06
Registration Form
確認書
Japanese 9.2 KB
2025-07-01 09:00
Annual Report
訂正有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 1.3 MB
2025-06-20 02:00
Post-Annual General Meeting Information
臨時報告書
Japanese 25.3 KB
2025-06-19 09:06
Share Issue/Capital Change
臨時報告書
Japanese 39.9 KB
2025-06-19 09:05
Share Issue/Capital Change
臨時報告書
Japanese 41.7 KB
2025-06-19 09:02
Governance Information
内部統制報告書-第77期(2024/04/01-2025/03/31)
Japanese 26.0 KB
2025-06-19 09:01
Registration Form
確認書
Japanese 9.2 KB
2025-06-19 09:00
Annual Report
有価証券報告書-第77期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2024-11-06 01:00
Interim Report
半期報告書-第77期(2024/04/01-2025/03/31)
Japanese 334.0 KB
2024-11-06 01:00
Interim Report
確認書
Japanese 9.1 KB
2024-06-21 02:05
Post-Annual General Meeting Information
臨時報告書
Japanese 27.2 KB
2024-06-21 02:04
Governance Information
内部統制報告書-第76期(2023/04/01-2024/03/31)
Japanese 24.4 KB
2024-06-21 02:03
Registration Form
確認書
Japanese 9.2 KB

Automate Your Workflow. Get a real-time feed of all ONO PHARMACEUTICAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ONO PHARMACEUTICAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ONO PHARMACEUTICAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE
MBX Biosciences, Inc. Logo
Developing novel peptide therapies for underserved endocrine and metabolic disorders.
United States of America
MBX
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea
233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan
4875
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece
MEDIC
MEDICOX Co., Ltd. Logo
Developing new drugs and building a distribution platform for healthcare solutions.
South Korea
054180
Medicus Pharma Ltd. Logo
A clinical-stage holding company advancing novel drugs, biologics, and devices to market.
United States of America
MDCX
Medigene AG Logo
Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.
Germany
MDG1
MedinCell S.A. Logo
Develops long-acting injectable therapies using proprietary technology to impact global health.
France
MEDCL
A CDMO for cell therapy and regenerative medicine development & manufacturing.
Japan
2370

Talk to a Data Expert

Have a question? We'll get back to you promptly.